<![CDATA[Withdrawal Planned for Second-Line Lurbinectedin in SCLC Indication]]>

Data ReadoutMixedlurbinectedinNegative

AI Analysis

Summary

Lurbinectedin's second-line SCLC indication will be withdrawn following LAGOON trial results, while the drug's first-line approval status remains unaffected.

Clinical Trial Data

Outcome Details

LAGOON trial results show withdrawal planned for second-line indication while first-line approval status remains unimpacted

Importance:5/10

Sentiment:

-0.30

oncologySCLCclinical_trialregulatoryindication_withdrawal

Related Companies

$TRAX

Read the original article

Published by Cancer Network on August 5, 2026 2:00 PM

Read Original